BACKGROUND: Angiosarcomas are an uncommon type of malignancy that are generally thought to behave usually in a locally aggressive fashion; they often metastasize to distant sites. METHODS: Patients with a diagnosis of angiosarcoma treated at our institution between 1980 and 2006 were analyzed for patient demographics, tumor characteristics, multimodality treatment, and outcomes. RESULTS: A total of 82 patients were divided into those with primary and advanced disease. Overall, the median age was 65 (range, 22-91) years, and 44% of patients were women. Median size of tumors was 3.8 cm, and 76% of tumors were intermediate or high grade. Tumors were located throughout the body: 32 cutaneous, 22 deep soft tissues or organs, 10 radiation or lymphedema field, 8 bone, and 7 nonirradiated breast. Of 46 patients with primary disease, all patients underwent surgical resection, 67% received radiotherapy, and 27% received chemotherapy. Five-year disease-specific survival was 60%, and negative prognostic factors included intermediate or high grade, and tumors arising in a radiated or lymphedema field. Of 36 patients with advanced disease, 36% underwent a palliative operation, 78% received radiation, and 58% received chemotherapy. Median survival was just 7.3 months, and cutaneous tumors predicted a better prognosis compared with other sites. CONCLUSIONS: Primary angiosarcomas treated with aggressive surgical resection and the addition of radiation for close margins or worrisome pathologic features can result in long-term survival in most patients. The role of adjuvant chemotherapy is unclear. Patients with advanced disease have a poor prognosis, but there can be dramatic responses to chemotherapy in a minority of patients.
BACKGROUND:Angiosarcomas are an uncommon type of malignancy that are generally thought to behave usually in a locally aggressive fashion; they often metastasize to distant sites. METHODS:Patients with a diagnosis of angiosarcoma treated at our institution between 1980 and 2006 were analyzed for patient demographics, tumor characteristics, multimodality treatment, and outcomes. RESULTS: A total of 82 patients were divided into those with primary and advanced disease. Overall, the median age was 65 (range, 22-91) years, and 44% of patients were women. Median size of tumors was 3.8 cm, and 76% of tumors were intermediate or high grade. Tumors were located throughout the body: 32 cutaneous, 22 deep soft tissues or organs, 10 radiation or lymphedema field, 8 bone, and 7 nonirradiated breast. Of 46 patients with primary disease, all patients underwent surgical resection, 67% received radiotherapy, and 27% received chemotherapy. Five-year disease-specific survival was 60%, and negative prognostic factors included intermediate or high grade, and tumors arising in a radiated or lymphedema field. Of 36 patients with advanced disease, 36% underwent a palliative operation, 78% received radiation, and 58% received chemotherapy. Median survival was just 7.3 months, and cutaneous tumors predicted a better prognosis compared with other sites. CONCLUSIONS:Primary angiosarcomas treated with aggressive surgical resection and the addition of radiation for close margins or worrisome pathologic features can result in long-term survival in most patients. The role of adjuvant chemotherapy is unclear. Patients with advanced disease have a poor prognosis, but there can be dramatic responses to chemotherapy in a minority of patients.
Authors: Sandra P D'Angelo; Rodrigo R Munhoz; Deborah Kuk; Johnathan Landa; Eliza W Hartley; Michael Bonafede; Mark A Dickson; Mrinal Gounder; Mary L Keohan; Aimee M Crago; Cristina R Antonescu; William D Tap Journal: Oncology Date: 2015-06-03 Impact factor: 2.935
Authors: Richard J Cassidy; Jeffrey M Switchenko; Melinda L Yushak; Nicholas Madden; Mohammad K Khan; David K Monson; Jonathan J Beitler; Jerome C Landry; Karen D Godette; Theresa W Gillespie; Kirtesh R Patel Journal: Surg Oncol Date: 2018-09-13 Impact factor: 3.279
Authors: Isidro Machado; Francisco Giner; Javier Lavernia; Julia Cruz; Víctor Traves; Celia Requena; Beatriz Llombart; José Antonio López-Guerrero; Antonio Llombart-Bosch Journal: Histol Histopathol Date: 2020-09-04 Impact factor: 2.303
Authors: Matthew Breen; Jaime F Modiano; Ingegerd Elvers; Kerstin Lindblad-Toh; Kate Megquier; Jason Turner-Maier; Ross Swofford; Jong-Hyuk Kim; Aaron L Sarver; Chao Wang; Sharadha Sakthikumar; Jeremy Johnson; Michele Koltookian; Mitzi Lewellen; Milcah C Scott; Ashley J Schulte; Luke Borst; Noriko Tonomura; Jessica Alfoldi; Corrie Painter; Rachael Thomas; Elinor K Karlsson Journal: Mol Cancer Res Date: 2019-09-30 Impact factor: 5.852
Authors: Darya Buehler; Stephanie R Rice; John S Moody; Patrick Rush; Gholam-Reza Hafez; Steven Attia; B Jack Longley; Kevin R Kozak Journal: Am J Clin Oncol Date: 2014-10 Impact factor: 2.339